Answers are grounded in this paper and cite their sources.
Prasugrel and ticagrelor prevent ischemic events after emergency PCI in STEMI, but optimal DAPT duration and management of high bleeding risk patients remain unresolved.
inhibitors, prasugrel and ticagrelor, have been clearly shown to prevent stent thrombosis and recurrent ischaemic events after emergency percutaneous coronary intervention in STEMI patients. Open issues remaining are the treatment of patients with high bleeding risk, such as the elderly and those requiring anticoagulation, as well as the duration of dual antiplatelet therapy after STEMI.
No takes yet. Share an insight, caveat, or question.
Savonitto et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: